Literature DB >> 10764968

Fluoroquinolone-resistant Haemophilus influenzae: frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America).

D J Biedenbach1, R N Jones.   

Abstract

The incidence of fluoroquinolone-resistant (FQR) Haemophilus influenzae and Moraxella catarrhalis isolated from clinical specimens remains very rare, and the identification of such strains has been previously limited to case reports from diverse geographic locations. During the 1997 through 1998 SENTRY Antimicrobial Surveillance Program, four FQR-H. influenzae (0.13% of all strains) and one FQR-M. catarrhalis strains were identified and confirmed as having elevated MICs to > or =5 FQ class drugs. Among H. influenzae strains, MICs to marketed FQs were > or =0.12 microg/ml with ciprofloxacin MIC results > or =8-fold higher than wild type susceptible strains. The FQR-H. influenzae isolates were then compared with two previously reported strains that were determined to be identical using ribotyping and other molecular methods. In contrast, the SENTRY isolates were all genetically distinct and had mutations in parC and/or gyrA. Isolates having the lowest MIC elevations had a single mutation in gyrA, while isolates with higher MICs had at least one mutation in both studied genes. In general, the single gyr A mutations involved the same position but differed in the amino acid substitution (Ser84Leu or Phe or Ala). The isolates reported outside the SENTRY Program (controls) had an unusual mutation in par C (Gly82Asp) and two mutations in gyr A; producing the highest recorded FQR MICs. The FQR-M. catarrhalis strain was discovered in late 1997 and has been reported before. Although detection of these FQR isolates remains at <1% of all contemporary H. influenzae and M. catarrhalis isolates, surveillance programs will be an important detection method to determine the extent of emerging novel resistance patterns among clinically prevalent fastidious pathogens.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10764968     DOI: 10.1016/s0732-8893(00)00110-3

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  11 in total

1.  In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.

Authors:  Laurel S Almer; Jennifer B Hoffrage; Erika L Keller; Robert K Flamm; Virginia D Shortridge
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

2.  Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin.

Authors:  Xinying Li; Noriel Mariano; James J Rahal; Carl M Urban; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

3.  In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens.

Authors:  Douglas J Biedenbach; Michael D Huband; Meredith Hackel; Boudewijn L M de Jonge; Daniel F Sahm; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

Review 4.  Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Authors:  Susan J Keam; Katherine F Croom; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Antimicrobial susceptibilities of 1,730 Haemophilus influenzae respiratory tract isolates in Spain in 1998-1999.

Authors:  F Marco; J García-de-Lomas; C García-Rey; E Bouza; L Aguilar; C Fernández-Mazarrasa
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

6.  In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.

Authors:  Angela M Nilius; Linus L Shen; Dena Hensey-Rudloff; Laurel S Almer; Jill M Beyer; Darlene J Balli; Yingna Cai; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

7.  Susceptibilities of fluoroquinolone-resistant Haemophilus parainfluenzae isolates from Japanese patients with respiratory infections to five fluoroquinolones and other antimicrobial agents.

Authors:  Hiromu Takemura; Shigemi Terakubo; Hiroyuki Yamamoto; Jingoro Shimada; Hideki Nakashima
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

8.  Reduced levofloxacin susceptibility in clinical respiratory isolates of Haemophilus influenzae is not yet associated with mutations in the DNA gyrase and topoisomerase II genes in Korea.

Authors:  In-Suk Kim; Nam Yong Lee; Sunjoo Kim; Chang-Seok Ki; Sun-Hee Kim
Journal:  Yonsei Med J       Date:  2011-01       Impact factor: 2.759

Review 9.  Guide to selection of fluoroquinolones in patients with lower respiratory tract infections.

Authors:  Wael E Shams; Martin E Evans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

10.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.